METADATA
last updated: 2026-03-01
file_name: _AI_Covid_Surveillance_Testing_Screening_Report.md
file_date: 2026-03-01
title: FloodLAMP Surveillance, Testing, and Screening During the COVID-19 Pandemic
category: regulatory
subcategory: surveillance
tags: surveillance, screening, testing, CLIA, FDA, CMS, CDC, regulatory-definitions, SCAN, wastewater, genomic-surveillance
source_file_type: md
xfile_type: NA
gfile_url: https://docs.google.com/document/d/1heuoMq2c0YUEPD1-UvgW1QFI4pLIUBel4-iGuJk6MoM
xfile_github_download_url: https://raw.githubusercontent.com/FocusOnFoundationsNonprofit/floodlamp-archive/main/regulatory/surveillance/_AI_Covid_Surveillance_Testing_Screening_Report.md
pdf_gdrive_url: NA
pdf_github_url: NA
conversion_input_file_type: NA
conversion: NA
license: CC BY 4.0 - https://creativecommons.org/licenses/by/4.0/
tokens: 8194
words: 4205
notes: Created by ChatGPT Pro 5.2 Extended during archive preparation. **NOT HUMAN VERIFIED - MAY CONTAIN ERRORS** Comprehensive report on surveillance, testing, and screening regulatory history during the COVID-19 pandemic, covering U.S. regulatory architecture (FDA/CMS/CDC), key case studies (SCAN, SafeGuard/New Trier, FloodLAMP), operational patterns, and post-PHE transitions. Prompt not included.
summary_short: Regulatory history and analysis of surveillance, testing, and screening distinctions during the COVID-19 pandemic, focusing on how "surveillance testing" was defined, contested, and regulated across U.S. programs (2020--2023). Covers FDA/CMS/CDC frameworks, key case studies (SCAN, SafeGuard/New Trier, FloodLAMP), wastewater and genomic surveillance, and post-PHE transitions, with appendices mapping FloodLAMP archive documents and primary sources.


CONTENT

## Executive summary
During COVID-19, U.S. testing split into three overlapping purposes--**diagnosis**, **screening**, and **surveillance**, but institutions often used the word *surveillance* to describe programs that looked, functioned, and felt like **screening** (routine testing of asymptomatic people to make individual decisions). That semantic slippage mattered because, in U.S. law and agency practice, whether a program is "diagnostic/screening" versus "surveillance" affects:
- whether a site needs to operate as a **CLIA-certified laboratory** (or send testing to one),
- whether a method must be **FDA-authorized/marketed** (e.g., EUA during the PHE),
- what **results** may be returned to individuals,
- what **reporting** is required to public health agencies, and
- who has oversight authority (CMS, FDA, state agencies, IRBs, or local public health departments).

A central dynamic of the pandemic was the attempt to scale fast, low-cost testing in schools, universities, and workplaces **before** regulators had simple, stable frameworks for frequent testing of asymptomatic people. Many programs therefore sought "escape hatches":
- **Research framing** (IRB oversight; results sometimes handled differently),
- **De-identified public health surveillance** (aggregate reporting; no individual results),
- **Pooled testing + referral** (only "pool-level detection," with confirmatory individual diagnostic tests elsewhere),
- **State authorization** (especially early 2020) before federal processes matured.

The canonical early collision between these worlds occurred in Seattle: the **Seattle Flu Study** (a pre-pandemic influenza surveillance platform) and its COVID-era successor **SCAN** (Greater Seattle Coronavirus Assessment Network) encountered shifting FDA interpretations about home collection and the return of results. In mid-May 2020, FDA-directed pauses and press coverage created a durable "object lesson" for how a program can be described as "surveillance" but become regulated once it returns individual results.

By 2021--2022, CMS (CLIA) and FDA guidance became more explicit about these distinctions, and regulators began pushing back when "surveillance" language appeared to mask **individual-result** testing--an issue that also appears in FloodLAMP's archive (e.g., FDA website review and requests to remove language implying individual follow-up testing).

By 2023, as the federal COVID-19 PHE ended, mandatory nationwide reporting and many emergency flexibilities wound down. Surveillance increasingly shifted toward **sentinel systems**, especially **wastewater surveillance** and **genomic surveillance**, because case-based counting (and universal negative-result reporting) became less feasible as home testing expanded and public reporting requirements changed.


## 1. Why "surveillance" became a contested label
### 1.1 Pre-pandemic baseline meaning
Before COVID-19, **public health surveillance** primarily meant population-level monitoring--collecting and analyzing data to track disease trends, detect outbreaks, and guide interventions. Surveillance generally did **not** mean providing an individual with a clinical test result to guide personal decisions.

### 1.2 COVID-era expansion and semantic drift
During COVID-19, "surveillance" was sometimes used more broadly to describe:
- routine testing programs for **asymptomatic** people (e.g., schools/workplaces), and/or
- pooled testing programs where administrators wanted to claim they were not doing clinical testing even while **removing individuals from school/work** based on results.

This produced a recurring tension:
- **Regulators** tended to treat "returning individual results" as the key feature that makes testing *clinical* (diagnostic or screening).
- **Operators** often used "surveillance" to signal a public-health purpose and to reduce friction, cost, or compliance burdens--especially for high-frequency testing.


## 2. Key definitions that shaped policy
The FDA's "COVID-19 Test Uses" FAQ (content current as of **September 29, 2023**) summarizes the triad as follows (paraphrased):

- **Diagnostic testing:** testing an individual when there is reason to suspect infection (symptoms or known/suspected exposure).
- **Screening testing:** testing an individual even without suspicion or known exposure, with the intent to make **individual decisions** based on results (e.g., school/workplace testing to decide who returns).
- **Surveillance testing:** systematic activities to generate **population-level** information, generally not reporting results to a patient or provider.

Source (FDA): `regulatory/surveillance/FDA Website - COVID-19 Test Uses_ FAQs on Testing for SARS-CoV-2 (updated 2023-09-29).md`
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/covid-19-test-uses-faqs-testing-sars-cov-2

### 2.1 A practical "surveillance vs screening" test
In practice, a useful question was:

> **Will anyone use this test result to make an individual decision about one person?**  
> If yes, regulators usually treated it as **screening or diagnostic**, not surveillance.


## 3. U.S. regulatory architecture in plain language
### 3.1 CLIA (CMS): "Are you operating a laboratory that returns patient-specific results?"
The Clinical Laboratory Improvement Amendments (**CLIA**) are administered by CMS and regulate laboratories that test human specimens for diagnosis, prevention, treatment, or health assessment. In general:

- If a program returns **patient-specific** results, it often triggers **CLIA** requirements.
- If a program is truly **de-identified** and results are not used for individual decisions, it can sometimes fall outside CLIA's clinical laboratory framework.

COVID-era complexity: CMS issued multiple FAQs and memos clarifying when pooled or surveillance workflows might proceed without a traditional CLIA certificate (often under time-limited enforcement discretion).

Post-PHE note: CMS emphasized that some flexibilities ended with the PHE and that its authority to require SARS-CoV-2 test reporting was linked to the federal PHE declaration.

Key sources:
- CMS QSO-23-15-CLIA (May 11, 2023): https://www.cms.gov/files/document/qso-23-15-clia.pdf  
- CMS "CLIA FAQs: Post-PHE Guidance" (May 11, 2023): https://www.cms.gov/files/document/clia-post-phe-guidance-faqs-only.pdf  
- CDC LOCS Lab Advisory on post-PHE CLIA reporting (May 19, 2023): https://www.cdc.gov/locs/2023/05-19-2023-Lab-Advisory-COVID-19_CLIA_Post-Public_Health_Emergency_Guidance.html  

### 3.2 FDA: "Are you using an in vitro diagnostic (IVD) test for a clinical purpose?"
In the U.S., SARS-CoV-2 tests are **medical devices** (IVDs) overseen by FDA. During the COVID-19 emergency, most tests entered the market via:

- **Emergency Use Authorizations (EUAs)**, and/or
- FDA's evolving testing **policies** (including enforcement discretion windows).

A recurring flashpoint was **home collection** and "direct-to-consumer" workflows. Early in the pandemic, FDA's policies for home collection and home testing shifted repeatedly, contributing to confusion among research and public-health programs (and to headline-grabbing conflicts such as SCAN).

### 3.3 CDC and public health agencies: "What is the public health function?"
CDC guidance documents helped define and compare diagnostic, screening, and surveillance strategies; they also reinforced that:

- diagnostic/screening testing intended to return results to individuals comes with clinical lab and reporting expectations,
- surveillance testing is typically de-identified and not returned to individuals.

The FloodLAMP archive includes a CDC "Testing Strategies for SARS-CoV-2" document updated December 28, 2021, which contains a summary matrix comparing these strategies. **FLAG - add relative path to file**


## 4. Timeline of key events (selected)
> This timeline is intentionally "U.S.-regulatory centered." It highlights moments when agency interpretation or public controversy changed how surveillance and screening were discussed.

| Date | Event | Why it matters for surveillance vs. screening |
|---|---|---|
| **Nov 2018** | Seattle Flu Study (SFS) established as a community respiratory surveillance platform | Built "pre-pandemic" surveillance infrastructure later repurposed for SARS-CoV-2. |
| **Feb 2020 (early)** | Seattle Flu Study begins seeking permission to use existing sample bank for SARS-CoV-2 surveillance | Shows early friction when research surveillance intersects with clinical/public health needs (discussed in ethics literature). |
| **Feb 24, 2020** | First SFS SARS-CoV-2 community transmission case detected (specimen collected Feb 24) | Widely cited example of surveillance detecting community spread early; paper notes Gates Ventures support. |
| **Mar 23, 2020** | SCAN launched (Seattle Flu Study + Public Health -- Seattle & King County) | Explicitly framed as a "disease surveillance platform." Also the date SCAN later cited as the start of its EUA process. |
| **May 11--12, 2020** | FDA clarifies home self-collection policy; SCAN directed to pause returning results pending additional federal authorization | Key inflection: "surveillance" + **returning individual results** triggered FDA expectations for EUA/authorization. |
| **Jun 10, 2020** | SCAN resumes testing; explains pause and EUA pathway | SCAN publicly documents its regulatory posture: surveillance framing, but acknowledgement of EUA needs for home collection + results return. |
| **Aug 28, 2020** | CMS publishes university lab testing / surveillance FAQ (CLIA) | Institutional testing programs scale; CMS addresses pooled testing and surveillance workflows. |
| **Dec 2020** | CMS issues notice letter on CLIA surveillance testing | Clarifies that returning patient-specific results generally triggers CLIA; describes enforcement discretion constraints. |
| **Mar 19, 2021** | CMS publishes variant testing FAQ | Extends "surveillance without individual return" logic into genomic/variant sequencing. |
| **Mar 30, 2021** | NYT story on New Trier High School testing scrutiny | A high-profile example of school testing being treated as regulated screening when individual students are flagged. |
| **Oct 21, 2021** | CMS revises surveillance testing FAQ | More mature articulation of pooled surveillance testing risks and confirmatory testing expectations. |
| **Dec 28, 2021** | CDC updates testing strategies guidance | Reinforces definitions and operational boundaries between diagnostic/screening vs surveillance. |
| **Jan--Mar 2022** | FDA correspondence with FloodLAMP regarding website claims | Illustrates late-pandemic tightening on "surveillance" branding when individual follow-up pathways are implied. |
| **May 11, 2023** | Federal COVID-19 PHE ends | Reporting requirements and emergency flexibilities change; surveillance systems (wastewater/genomic) become relatively more central. |
| **Sep 29, 2023** | FDA updates "COVID-19 Test Uses" FAQ | A consolidated, post-crisis articulation of diagnostic vs screening vs surveillance definitions. |

Primary source links for the Seattle portion of this timeline are in the next section.


## 5. Case studies and major programs
### 5.1 Seattle Flu Study -> SCAN (Greater Seattle Coronavirus Assessment Network)
**Why this matters:** This is one of the clearest public examples of a pre-pandemic *influenza surveillance* platform being repurposed for SARS-CoV-2, and then colliding with regulatory boundaries when results were returned.

#### 5.1.1 Seattle Flu Study as "pandemic surveillance platform"
A short NEJM letter by Chu et al. describes the Seattle Flu Study as a multi-institutional pandemic surveillance platform established in **November 2018**, and reports early detection of SARS-CoV-2 community transmission through that infrastructure. The letter's disclosure footnote notes **Gates Ventures** support.
- NEJM (full text): https://www.nejm.org/doi/full/10.1056/NEJMc2008646  
- Open-access mirror (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC7206929/

#### 5.1.2 Launch of SCAN as a public health surveillance program
Public Health -- Seattle & King County announced SCAN on **March 23, 2020**, describing it as a disease surveillance platform to better understand how COVID-19 was spreading.
- Public Health Insider (Mar 23, 2020): https://publichealthinsider.com/2020/03/23/introducing-scan-the-greater-seattle-coronavirus-assessment-network/  
- SCAN Technical Report (Apr 17, 2020 PDF): https://publichealthinsider.com/wp-content/uploads/2020/04/SCAN-Technical-Report-v1-17-APR-2020.pdf  

#### 5.1.3 The May 2020 pause and "the surveillance/screening collision"
In May 2020, SCAN paused returning results after FDA clarified policy for **home-based, self-collected samples** and indicated that **a separate federal EUA** was required to return results for self-collected tests.

Primary/near-primary sources documenting this sequence:
- Public Health Insider "SCAN resumes" explanation (Jun 10, 2020): https://publichealthinsider.com/2020/06/10/greater-seattle-coronavirus-assessment-network-scan-resumes-covid-19-testing/  
- Reuters coverage of the pause (May 16--17, 2020): https://www.reuters.com/article/world/u-s-fda-suspends-gates-backed-at-home-covid-19-testing-program-idUSKBN22S0R7/  
- STAT analysis and quotes from FDA + experts (May 27, 2020): https://www.statnews.com/2020/05/27/coronavirus-testing-seattle-bill-gates-fda/  

**Key regulatory lesson illustrated:**  
Even if a program's *purpose* is public health surveillance, **returning results to individuals**--especially in a home-collection workflow--pulled the program into FDA/CMS compliance expectations typical of screening/diagnostic testing.

#### 5.1.4 Ethical framing: research infrastructure repurposed for public health
Legal/ethics scholarship used the Seattle Flu Study as an example of the complexities of using research infrastructure for urgent public health purposes, including result return and reporting mandates.

- Doerr et al. (Journal of Law and the Biosciences, 2020; open access): https://pmc.ncbi.nlm.nih.gov/articles/PMC7381975/  


### 5.2 School-based saliva surveillance: Ed Campbell (SafeGuard) and the New Trier example
**Why this matters:** K-12 schools became a major arena where "surveillance testing" was used colloquially to mean frequent testing, but regulators often treated it as **screening** because individual students were identified and acted upon.

#### 5.2.1 Ed Campbell and SafeGuard surveillance / Safeguard Solutions
Multiple media and case-study sources describe Dr. **Ed Campbell** (a virologist and Loyola University Chicago faculty member) as an organizer of school testing efforts under the company **Safeguard Solutions** (which later obtained CLIA certification) and link the saliva test lineage to collaboration with U Madison scientist **David (Dave) O'Connor**.
- Hinsdale Magazine profile (Apr 2021): https://hinsdalemag.com/keeping-the-doors-open/  
- Gilson "Safeguard Solutions: A COVID-19 Student Testing Operation" (case study): https://www.gilson.com/us/case-study-safeguard-solutions-a-covid-19-student-testing-operation  

#### 5.2.2 New Trier High School and "surveillance" vs "screening"
The New York Times story
`regulatory/surveillance/2021-03-30_NY Times - Why Virus Tests at One Elite School Ran Afoul of Regulators.md`
https://www.nytimes.com/2021/03/30/us/covid-school-testing-fda.html
is frequently cited because it shows the operational boundary regulators cared about:
- If a test flags **specific students** and triggers individual action (send home, isolate, etc.), regulators tend to treat that as **screening/clinical testing**, not de-identified public health surveillance.
- The resolution pathway described in coverage often involved moving toward CLIA-aligned operations and qualified oversight.


### 5.3 Dave O'Connor (University of Wisconsin): mobile RT-LAMP surveillance and genomic surveillance
**Why this matters:** O'Connor's work appears in two "surveillance" modes:
1) **frequent, low-friction saliva testing** (often RT-LAMP) to support safer schools/workplaces, and  
2) **genomic surveillance** (sequencing) to track viral spread and variants.

#### 5.3.1 Mobile saliva RT-LAMP as a surveillance tool (summer--fall 2020)
UW researchers evaluated a mobile, outdoor RT-LAMP workflow using saliva samples from volunteers, emphasizing that it was oriented toward surveillance and rapid turnaround rather than traditional clinical diagnostics.
- Newman et al., "Initial evaluation of a mobile SARS-CoV-2 RT-LAMP testing strategy" (open access, 2021): https://pmc.ncbi.nlm.nih.gov/articles/PMC7809916/  
  - (Paper describes surveillance samples collected July--Nov 2020.)

UW communications also described RT-LAMP as not yet approved for clinical diagnosis and advised confirmatory PCR for people who screened positive:
- UW News (Aug 6, 2020): https://news.wisc.edu/uw-researchers-develop-new-method-to-test-for-covid-19/  

Popular media coverage captured the "DIY/surveillance" framing and the regulatory barrier:
- WIRED (Jul 23, 2020): https://www.wired.com/story/a-wisconsin-city-experiments-with-a-faster-diy-covid-19-test  

#### 5.3.2 Scaling school testing and related grants
Wisconsin-focused reporting described efforts to improve school testing (including interest in methods like RT-LAMP):
- Pediatrics Wisconsin (Jul 23, 2021): https://pediatricswi.org/new-grant-aims-to-improve-testing-in-wisconsin-schools/  

#### 5.3.3 Genomic surveillance leadership in Dane County
University of Wisconsin communications described how researchers (including David O'Connor) contributed to viral sequencing surveillance in Dane County, positioning the area as unusually advanced in surveillance density during outbreaks.
- UW--Madison / Wisconsin.edu story (Oct 8, 2020): https://news.wisc.edu/residence-hall-outbreak-shows-virus-can-spread-quickly-even-when-precautions-taken/  


### 5.4 FloodLAMP pooled "non-diagnostic surveillance testing" and 2022 FDA correspondence (archive-based)
**Why this matters:** FloodLAMP's archive reflects an approach many pandemic-era programs attempted: structure testing as **non-diagnostic surveillance**--often pooled--where results are not returned as patient-specific positives/negatives, and individuals are referred to CLIA diagnostic testing when a pool indicates SARS-CoV-2 presence.

Relevant FloodLAMP Archive files include:
- **Internal regulatory framing memos** (Aug 2021, Jan 2021, Sept 2021) arguing that pooled surveillance with non-patient-specific reporting can fall outside CLIA/FDA requirements if individual results are not returned.
- **A "Non-Diagnostic Surveillance Testing Materials Acknowledgment and Waiver"** describing participant notification/referral, non-FDA authorization status, and a liability waiver.
- **FDA email correspondence (Jan--Mar 2022)** in which FDA staff flagged website language that seemed to imply individual clinical follow-up testing by FloodLAMP and requested revisions to align with FDA's policy framing of surveillance vs screening.

**Interpretive note:**  
These materials fit into a broader pandemic pattern: many operators sought to preserve speed/scale by using "surveillance" logic (aggregate reporting + referral), while regulators focused on whether the program's real-world operations or marketing implied individual diagnosis/screening.

(See Appendix A for the archive file list and where each document fits.)


## 6. Other major U.S. surveillance modalities that expanded during COVID
The term "surveillance" during COVID often refers to wastewater surveillance or genomic/variant surveillance.

### 6.1 Wastewater surveillance
Wastewater surveillance measures SARS-CoV-2 RNA shed into sewage, providing community-level signals that are independent of clinical testing access and not impacted by whether individuals seek tests.

CDC launched the **National Wastewater Surveillance System (NWSS)** in **September 2020** and continued to expand it.

- CDC AMD "Wastewater Surveillance: A New Frontier" (Apr 15, 2024; includes launch date + scale claims): https://www.cdc.gov/advanced-molecular-detection/php/success-stories/wastewater-surveillance.html  
- CDC NWSS "About" page: https://www.cdc.gov/nwss/about.html  
- CDC NWSS national data view: https://www.cdc.gov/nwss/rv/COVID19-national-data.html  

Late-pandemic significance: when many infections were detected via home tests that never entered official reporting systems, wastewater became a key "sentinel" indicator.

### 6.2 Genomic/variant surveillance
Genomic surveillance tracks viral evolution and spread by sequencing SARS-CoV-2. The U.S. scaled genomic surveillance substantially after a slow start.

Federal coordination examples:
- CDC press release launching **SPHERES** consortium (May 1, 2020; archived): https://archive.cdc.gov/www_cdc_gov/media/releases/2020/p0501-SARS-CoV-2-transmission-map.html  
- CDC "SPHERES" success story (Apr 12, 2024): https://www.cdc.gov/advanced-molecular-detection/php/success-stories/spheres.html  

A major CDC-affiliated pipeline is the **National SARS-CoV-2 Strain Surveillance (NS3)** program:
- APHL NS3 overview: https://www.aphl.org/programs/infectious_disease/SARS-CoV-2/Pages/Sequence-Based-Surveillance-Submission.aspx  
- CDC "Variants and Genomic Surveillance" page (updated Aug 28, 2025): https://www.cdc.gov/covid/php/variants/variants-and-genomic-surveillance.html  

### 6.3 Serosurveillance (antibody surveys)
Because case counts under-captured true infection prevalence--especially early--serosurveillance programs used blood donors and residual sera to estimate the proportion of the population with SARS-CoV-2 antibodies.

Examples of CDC-supported data products:
- CDC Data: Nationwide Commercial Laboratory Seroprevalence Survey: https://data.cdc.gov/Laboratory-Surveillance/Nationwide-Commercial-Laboratory-Seroprevalence-Su/d2tw-32xv  
- CDC Data: 2020--2021 Nationwide Blood Donor Seroprevalence Survey: https://data.cdc.gov/Laboratory-Surveillance/2020-2021-Nationwide-Blood-Donor-Seroprevalence-Su/wi5c-cscz  

### 6.4 Syndromic surveillance and "non-test" data streams
As routine lab reporting became less comprehensive, syndromic surveillance (e.g., emergency department data) and other indicators were increasingly used to track trends. Media coverage around the end of the federal PHE highlighted a shift from "count every case" toward sentinel systems such as hospital admissions + wastewater.

(One accessible overview of this shift:)
- TIME (May 2023): https://time.com/6277396/covid-19-data-public-health-emergency-ends/  


## 7. Operational patterns: how programs tried to stay on the "surveillance" side of the line

This section turns the definitions into concrete program design patterns seen in COVID-era "surveillance testing."

### 7.1 A simplified decision tree (conceptual)

```
TESTING PROGRAM
      |
      v
Are results used for individual decisions
or returned to a person/provider?
      |
  YES |                              NO
      v                               v
DIAGNOSTIC or SCREENING         Are specimens de-identified and
      |                         only aggregate/cohort results reported?
      |                               |
      |---> CLIA-certified       YES  |              NO / UNCLEAR
      |     testing site              v                    v
      |     (or send to          PUBLIC HEALTH        HIGH RISK of being
      |     CLIA lab)            SURVEILLANCE         treated as screening
      |                          PARADIGM             / clinical testing
      |---> FDA-authorized/           |
      |     marketed test             |---> Often described as outside
      |     (e.g., EUA during         |     FDA/CLIA clinical frameworks
      |     PHE)                      |     if no individual results
      |                               |
      |---> Individual reporting      |---> Still may require public health
            + public health                 coordination, ethics review,
            reporting                       and careful communication
```

**Caution:** During COVID, agencies also cared about *marketing/communications* (how a program described itself) and whether a "surveillance" workflow *functionally* produced patient-specific outputs (even if framed carefully).

### 7.2 A common "pooled surveillance + referral" workflow
Many programs used a structure like:
1. **Collect samples** (often saliva or anterior nares) from a defined group (classroom, team, work unit).
2. **Pool samples** (combine into one test reaction).
3. If the pool shows evidence of SARS-CoV-2, **notify the group** (or the institution) at a cohort level.
4. **Refer individuals** to a CLIA-certified diagnostic test for confirmatory individual results.

Regulatory rationale:
- Step (3) attempts to avoid returning **individual** results while still enabling mitigation.
- Step (4) is designed so that any individual medical decision rests on a CLIA/FDA-compliant diagnostic test.

This logic appears in multiple CMS CLIA surveillance documents (in your archive) and in many school/university programs.

### 7.3 The "communication failure mode"
In multiple high-profile controversies (SCAN, school programs, later FDA website reviews), a recurring issue was when a program:

- described itself as "surveillance," but
- provided participant-facing language that implied **individual follow-up testing** by the same non-CLIA/non-EUA pathway, or implied that results could be used as diagnostic information.

This "communication layer" is often where programs were challenged, even when their technical workflow was intended to remain surveillance-oriented.


## 8. Late-pandemic transition and follow-up events (2022--2025 context)

### 8.1 Post-PHE CLIA reporting changes (May 2023)
CMS emphasized that:
- its authority to require SARS-CoV-2 test result reporting was tied to the federal PHE declaration, and
- certain enforcement discretions/flexibilities would terminate with the PHE.

Primary sources:
- CMS QSO-23-15-CLIA memo (May 11, 2023): https://www.cms.gov/files/document/qso-23-15-clia.pdf  
- CMS post-PHE CLIA FAQs (May 11, 2023): https://www.cms.gov/files/document/clia-post-phe-guidance-faqs-only.pdf  
- CDC LOCS advisory (May 19, 2023) advising labs to check state reporting requirements: https://www.cdc.gov/locs/2023/05-19-2023-Lab-Advisory-COVID-19_CLIA_Post-Public_Health_Emergency_Guidance.html  

### 8.2 The "surveillance backbone" becomes wastewater + sentinel sampling
As case counting and universal lab reporting became less comprehensive, surveillance increasingly leaned on:
- wastewater (NWSS),
- sentinel lab networks,
- syndromic surveillance (ED data),
- and genomic surveillance pipelines.

This was not a sudden invention; rather, COVID accelerated investment and normalization of these methods, which then persisted because they remained informative even as individual testing behavior changed.


## 9. Lessons learned (research framing)
These are research/archival interpretations - useful as themes for an archive, not as prescriptions.

1. **Terminology needs operational anchors.** "Surveillance" should not be defined by intent alone; it must be defined by whether individual results are returned or used for individual decisions.
2. **Regulators respond to the full system, not just the assay.** Sample collection logistics, lab certification, reporting pipelines, and participant communications can each "flip" a program into the clinical category.
3. **Home collection is a special sensitivity.** SCAN shows how home-collection workflows triggered heightened FDA attention early in the pandemic.
4. **Pooled surveillance + referral was a scalable compromise.** It offered a way to monitor and mitigate spread while keeping clinical result return in CLIA-certified settings.
5. **Late-pandemic surveillance is increasingly environmental + sentinel.** Wastewater and genomic surveillance became critical as home testing eroded case-based counting.
6. **Archival value:** programs like FloodLAMP, SafeGuard, and SCAN are valuable not only technically but as evidence of how institutions navigated ambiguous regulatory boundaries under emergency conditions.


## Appendix A -- FloodLAMP archive pointers (regulatory/surveillance subcategory)
Below is the list you provided (file names + short summaries). These documents are useful "anchor texts" for reconstructing the surveillance-testing regulatory story as experienced by operators.

1. **2021-03-30_NY Times - Why Virus Tests at One Elite School Ran Afoul of Regulators.md**  
   NYT narrative of New Trier High School testing scrutiny; highlights confusion between "surveillance" and regulated screening.

2. **CDC - Testing Strategies for SARS-CoV-2 (includes Surveillance 12-28-2021).md**  
   CDC definitions/contrast of diagnostic, screening, and public health surveillance testing, including a summary matrix.

3. **CMS - CLIA SARS-CoV-2 Variant Testing Frequently Asked Question (2021-03-19).md**  
   CMS positions sequencing-based surveillance as potentially non-CLIA if not reported to individuals; discusses limited enforcement discretion for public health reporting.

4. **CMS - CLIA Surveillance Testing SARS-CoV-2 Frequently Asked Questions (2021-10-21).md**  
   CMS description of pooled surveillance testing, risks, and confirmatory testing expectations.

5. **CMS - CLIA University Lab Testing FAQ (2020-08-28).md**  
   CMS explanation of when surveillance testing requires CLIA, including pooled cohort reporting and enforcement discretion pathways.

6. **CMS Notice Letter - RE CLIA SURVEILLANCE TESTING (Dec 2020).md**  
   Clarifies when a facility becomes a CLIA-regulated lab and describes temporary enforcement discretion for surveillance workflows.

7. **FDA Warning Emails to FloodLAMP - Re_ Testing Clinical COVID-19 Samples (March 2022).md**  
   FDA outreach after reviewing FloodLAMP's website; requests revisions where surveillance language implied individual follow-up testing by FloodLAMP.

8. **FDA Website - COVID-19 Test Uses_ FAQs on Testing for SARS-CoV-2 (updated 2023-09-29).md**  
   FDA definitions and examples of diagnostic vs screening vs surveillance; setting/CLIA mapping for EUAs and traditional authorizations.

9. **FloodLAMP Non-Diagnostic Surveillance Testing Materials Acknowledgment and Waiver.md**  
   Entity-facing agreement clarifying non-diagnostic status, no individual results, and referral requirements; includes liability waiver.

10. **FloodLAMP Surveillance FAQ and Links (June 2022 DRAFT).md**  
    Contrasts diagnostic and surveillance testing; quotes CMS/FDA guidance about surveillance being outside CLIA/FDA when no individual results returned.

11. **FloodLAMP Surveillance Information (Aug 2021 INTERNAL).md**  
    Internal memo on regulatory framing for pooled non-diagnostic surveillance; cites CMS enforcement discretion and research-lab exemptions.

12. **Memo - Surveillance Authority Plain-language Research (Jan 2021 from Senior Medical Director in Healthcare Industry).md**  
    Plain-language digest of FDA/CMS surveillance framing and conditions under which presumptive positives may be routed to CLIA confirmatory testing.

13. **Memo - USA Surveillance Strategy (Sept 2021 from non-FloodLAMP Healthcare Attorney).md**  
    Notes surveillance testing generally not regulated when de-identified and no individual results returned; recommends coordination with public health and careful cohort sizing.


## Appendix B -- Selected primary sources and "high-signal" reading list
### B1. FDA (definitions, policies, and context)
- FDA "COVID-19 Test Uses: FAQs on Testing for SARS-CoV-2" (definitions; updated 9/29/23):
  `regulatory/surveillance/FDA Website - COVID-19 Test Uses_ FAQs on Testing for SARS-CoV-2 (updated 2023-09-29).md`
  https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/covid-19-test-uses-faqs-testing-sars-cov-2
- FDA "FAQs on Testing for SARS-CoV-2" (developer-focused; updated 11/8/23):  
  https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/faqs-testing-sars-cov-2
- FDA "Historical Information about Device Emergency Use Authorizations" (revoked/expired EUAs, revocation letters; updated 2026):  
  https://www.fda.gov/medical-devices/emergency-use-authorizations-medical-devices/historical-information-about-device-emergency-use-authorizations

### B2. CMS / CLIA (post-PHE guidance and key memos)
- CMS QSO-23-15-CLIA (post-PHE changes; 5/11/2023): https://www.cms.gov/files/document/qso-23-15-clia.pdf  
- CMS post-PHE CLIA FAQs (5/11/2023): https://www.cms.gov/files/document/clia-post-phe-guidance-faqs-only.pdf  
- CMS "Infectious diseases" landing page (links to CLIA COVID PDFs, including surveillance testing FAQ):  
  https://www.cms.gov/about-cms/what-we-do/emergency-response/past-emergencies/infectious-diseases

### B3. Seattle surveillance (Seattle Flu Study / SCAN) -- the FDA/Gates touchpoint
- NEJM: "Early Detection of Covid-19 through a Citywide Pandemic Surveillance Platform" (Chu et al.):  
  https://www.nejm.org/doi/full/10.1056/NEJMc2008646
- Public Health Insider: SCAN launch (Mar 23, 2020):  
  https://publichealthinsider.com/2020/03/23/introducing-scan-the-greater-seattle-coronavirus-assessment-network/
- Public Health Insider: SCAN resumes + pause explanation (Jun 10, 2020):  
  https://publichealthinsider.com/2020/06/10/greater-seattle-coronavirus-assessment-network-scan-resumes-covid-19-testing/
- Reuters: FDA suspends Gates-backed at-home COVID-19 testing program (May 2020):  
  https://www.reuters.com/article/world/u-s-fda-suspends-gates-backed-at-home-covid-19-testing-program-idUSKBN22S0R7/
- STAT: "Experts decry FDA's halting of a high-profile Covid-19 study..." (May 27, 2020):  
  https://www.statnews.com/2020/05/27/coronavirus-testing-seattle-bill-gates-fda/

### B4. School/community surveillance linked to Ed Campbell and Dave O'Connor
- Hinsdale Magazine: "Keeping the Doors OPEN" (SafeGuard; Campbell + O'Connor linkage):  
  https://hinsdalemag.com/keeping-the-doors-open/
- Gilson case study: Safeguard Solutions student testing operation:  
  https://www.gilson.com/us/case-study-safeguard-solutions-a-covid-19-student-testing-operation
- UW News: UW researchers develop saliva RT-LAMP testing method (Aug 6, 2020):  
  https://news.wisc.edu/uw-researchers-develop-new-method-to-test-for-covid-19/
- Newman et al. (2021, open access): mobile RT-LAMP testing strategy:  
  https://pmc.ncbi.nlm.nih.gov/articles/PMC7809916/
- WIRED: Wisconsin DIY/LAMP testing + O'Connor quotes (Jul 23, 2020):  
  https://www.wired.com/story/a-wisconsin-city-experiments-with-a-faster-diy-covid-19-test/
- UW story on Dane County outbreak + sequencing surveillance (Oct 8, 2020):  
  https://news.wisc.edu/residence-hall-outbreak-shows-virus-can-spread-quickly-even-when-precautions-taken/

### B5. Wastewater & genomic surveillance (late-pandemic backbone)
- CDC NWSS overview: https://www.cdc.gov/nwss/about.html  
- CDC wastewater surveillance success story (includes 2020 launch claim):  
  https://www.cdc.gov/advanced-molecular-detection/php/success-stories/wastewater-surveillance.html
- CDC SPHERES launch press release (May 1, 2020; archived):  
  https://archive.cdc.gov/www_cdc_gov/media/releases/2020/p0501-SARS-CoV-2-transmission-map.html
- APHL NS3 overview:  
  https://www.aphl.org/programs/infectious_disease/SARS-CoV-2/Pages/Sequence-Based-Surveillance-Submission.aspx

### B6. Legal/policy analysis (useful for contextualizing archival documents)
- Yale Law Journal Forum: "Deadly Delay: The FDA's Role in America's COVID-Testing Debacle" (Rao, 2020):  
  https://yalelawjournal.org/essay/deadly-delay-the-fdas-role-in-americas-covid-testing-debacle